메뉴 건너뛰기




Volumn 31, Issue 34, 2013, Pages 4362-4370

American society of clinical oncology 2013 top five list in oncology

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PREVENTION; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL SOCIETY; ONCOLOGY; PATIENT CARE; PRIORITY JOURNAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; MOLECULARLY TARGETED THERAPY; MULTIMODAL IMAGING; PATIENT SELECTION; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; STANDARD; UNITED STATES; UNNECESSARY PROCEDURE; STANDARDS;

EID: 84892900404     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.3943     Document Type: Article
Times cited : (116)

References (55)
  • 1
    • 79251470391 scopus 로고    scopus 로고
    • Projections of the cost of cancer care in the United States: 2010-2020
    • Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
    • (2011) J Natl Cancer Inst , vol.103 , pp. 117-128
    • Mariotto, A.B.1    Yabroff, K.R.2    Shao, Y.3
  • 2
    • 33847676571 scopus 로고    scopus 로고
    • Centers for Medicare and Medicaid Services: National health expenditures projections 2011-2021. http:// www.cms.gov/Research-Statistics-data-and-Systems/ Statistics-Trends-and-Reports/NationalHealth ExpendData/Downloads/Proj2011PDF. pdf
    • National Health Expenditures Projections
  • 3
    • 84863195517 scopus 로고    scopus 로고
    • American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology
    • Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715- 1724, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 1715-1724
    • Schnipper, L.E.1    Smith, T.J.2    Raghavan, D.3
  • 4
    • 84864976091 scopus 로고    scopus 로고
    • When the cost curve bent: Pre-recession moderation in health care spending
    • Roehrig C, Turner A, Hughes-Cromwick P, et al: When the cost curve bent: Pre-recession moderation in health care spending. N Engl J Med 367: 590-593, 2012
    • (2012) N Engl J Med , vol.367 , pp. 590-593
    • Roehrig, C.1    Turner, A.2    Hughes-Cromwick, P.3
  • 6
    • 80755126820 scopus 로고    scopus 로고
    • Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    • Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 4189-4198
    • Basch, E.1    Prestrud, A.A.2    Hesketh, P.J.3
  • 7
    • 58749100277 scopus 로고    scopus 로고
    • Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial
    • Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
    • (2009) Lancet Oncol , vol.10 , pp. 115-124
    • Saito, M.1    Aogi, K.2    Sekine, I.3
  • 8
    • 77953349334 scopus 로고    scopus 로고
    • Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    • Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
    • (2010) Ann Oncol , vol.21 , pp. 1083-1088
    • Aapro, M.1    Fabi, A.2    Nolè, F.3
  • 9
    • 57849152399 scopus 로고    scopus 로고
    • The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
    • Yu Z, Liu W, Wang L, et al: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99-102, 2009
    • (2009) Support Care Cancer , vol.17 , pp. 99-102
    • Yu, Z.1    Liu, W.2    Wang, L.3
  • 10
    • 84862544485 scopus 로고    scopus 로고
    • 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1)
    • Cardoso F, Costa A, Norton L, et al: 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1). Breast 21:242-252, 2012
    • (2012) Breast , vol.21 , pp. 242-252
    • Cardoso, F.1    Costa, A.2    Norton, L.3
  • 11
    • 70349260426 scopus 로고    scopus 로고
    • Single agent versus combination chemotherapy for metastatic breast cancer
    • Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372, 2009
    • (2009) Cochrane Database Syst Rev , vol.15
    • Carrick, S.1    Parker, S.2    Thornton, C.E.3
  • 14
    • 84876970810 scopus 로고    scopus 로고
    • Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    • Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
    • (2013) Lancet Oncol , vol.14 , pp. 461-471
    • Swain, S.M.1    Kim, S.B.2    Cortés, J.3
  • 15
    • 0037102121 scopus 로고    scopus 로고
    • Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    • Howell A, Robertson JF, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 3396-3403
    • Howell, A.1    Robertson, J.F.2    Quaresma Albano, J.3
  • 16
    • 79951956249 scopus 로고    scopus 로고
    • Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline
    • Lutz S, Berk L, Chang E, et al: Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965-976, 2011
    • (2011) Int J Radiat Oncol Biol Phys , vol.79 , pp. 965-976
    • Lutz, S.1    Berk, L.2    Chang, E.3
  • 20
    • 84905915734 scopus 로고    scopus 로고
    • Cancer Care Ontario
    • Cancer Care Ontario: PET imaging in Ontario. http://www.cancercare.on.ca/ ocs/clinicalprogs/imaging/ pet
    • PET Imaging in Ontario
  • 21
    • 77954320936 scopus 로고    scopus 로고
    • Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and followup
    • Labianca R, Norlinger B Becotta GD, et al: Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and followup. Ann Oncol 21:v70-v77, 2010 (suppl 5)
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • Labianca, R.1    Norlinger, B.2    Becotta, G.D.3
  • 22
    • 84881115822 scopus 로고    scopus 로고
    • Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
    • Cheah CY, Hofman MS, Dickinson M, et al: Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109:312-317, 2013
    • (2013) Br J Cancer , vol.109 , pp. 312-317
    • Cheah, C.Y.1    Hofman, M.S.2    Dickinson, M.3
  • 24
    • 79551559469 scopus 로고    scopus 로고
    • Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer
    • Evangelista L, Baretta, Vinante L, et al: Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 38:293-301, 2011
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 293-301
    • Evangelista, L.1    Baretta2    Vinante, L.3
  • 26
    • 84890917324 scopus 로고    scopus 로고
    • Utility of post-therapy surveillance scans in DCBCL
    • abstr 8504
    • Thompson CA, Maurer MJ, Ghesquieres H, et al: Utility of post-therapy surveillance scans in DCBCL. J Clin Oncol 31:519s, 2013 (suppl; abstr 8504)
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL.
    • Thompson, C.A.1    Maurer, M.J.2    Ghesquieres, H.3
  • 27
    • 84892978390 scopus 로고    scopus 로고
    • Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
    • abstr 8505
    • Pingali SR, Sewell S, Havlat L, et al: Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 31:519s, 2013 (suppl; abstr 8505)
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL.
    • Pingali, S.R.1    Sewell, S.2    Havlat, L.3
  • 28
    • 84872945000 scopus 로고    scopus 로고
    • PSA: Please stop agonizing (over prostate-specific antigen interpretation)
    • Raghavan D: PSA: Please stop agonizing (over prostate-specific antigen interpretation). Mayo Clin Proc 88:1-3, 2013
    • (2013) Mayo Clin Proc , vol.88 , pp. 1-3
    • Raghavan, D.1
  • 29
    • 0019442199 scopus 로고
    • Use of human prostate-specific antigen in monitoring prostate cancer
    • Kuriyama M, Wang MC, Lee CI, et al: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874-3876, 1981 (Pubitemid 11011166)
    • (1981) Cancer Research , vol.41 , Issue.10 , pp. 3874-3876
    • Kuriyama, M.1    Wang, M.C.2    Lee, C.3
  • 30
    • 82255162851 scopus 로고    scopus 로고
    • Baseline prostate-specific antigen testing at a young age
    • Loeb S, Carter HB, Catalona WJ, et al: Baseline prostate-specific antigen testing at a young age. Eur Urol 61:1-7, 2012
    • (2012) Eur Urol , vol.61 , pp. 1-7
    • Loeb, S.1    Carter, H.B.2    Catalona, W.J.3
  • 31
    • 63249118690 scopus 로고    scopus 로고
    • Screening and prostate-cancer mortality in a randomized European study
    • Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320- 1328, 2009
    • (2009) N Engl J Med , vol.360 , pp. 1320-1328
    • Schröder, F.H.1    Hugosson, J.2    Roobol, M.J.3
  • 32
    • 84858212484 scopus 로고    scopus 로고
    • Prostate-cancer mortality at 11 years of follow-up
    • Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
    • (2012) N Engl J Med , vol.366 , pp. 981-990
    • Schröder, F.H.1    Hugosson, J.2    Roobol, M.J.3
  • 33
    • 77955279420 scopus 로고    scopus 로고
    • Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
    • Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
    • (2010) Lancet Oncol , vol.11 , pp. 725-732
    • Hugosson, J.1    Carlsson, S.2    Aus, G.3
  • 34
    • 63249122661 scopus 로고    scopus 로고
    • Mortality results from a randomized prostatecancer screening trial
    • Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostatecancer screening trial. N Engl J Med 360:1310-1319, 2009
    • (2009) N Engl J Med , vol.360 , pp. 1310-1319
    • Andriole, G.L.1    Crawford, E.D.2    Grubb III, R.L.3
  • 37
    • 84878101564 scopus 로고    scopus 로고
    • Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians
    • Qaseem A, Barry MJ, Denberg TD, et al: Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 158:761-769, 2013
    • (2013) Ann Intern Med , vol.158 , pp. 761-769
    • Qaseem, A.1    Barry, M.J.2    Denberg, T.D.3
  • 38
    • 84880005911 scopus 로고    scopus 로고
    • Early detection of prostate cancer: AUA Guideline
    • Carter HB, Albertson PC, Barry MJ, et al: Early detection of prostate cancer: AUA Guideline. J Urol 190:419-426, 2013
    • (2013) J Urol , vol.190 , pp. 419-426
    • Carter, H.B.1    Albertson, P.C.2    Barry, M.J.3
  • 39
    • 84865213012 scopus 로고    scopus 로고
    • Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion
    • Basch E, Oliver TK, Vickers A, et al: Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 30:3020-3025, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 3020-3025
    • Basch, E.1    Oliver, T.K.2    Vickers, A.3
  • 40
    • 0021811764 scopus 로고
    • Structural organization of the bcr gene and its role in the Ph' translocation
    • DOI 10.1038/315758a0
    • Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-761, 1985 (Pubitemid 15022931)
    • (1985) Nature , vol.315 , Issue.6022 , pp. 758-761
    • Heisterkamp, N.1    Stam, K.2    Groffen, J.3
  • 42
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
    • (2013) N Engl J Med , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3
  • 43
    • 84884736973 scopus 로고    scopus 로고
    • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    • Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 3327-3334
    • Sequist, L.V.1    Yang, J.C.2    Yamamoto, N.3
  • 44
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 45
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694- 1703, 2012
    • (2012) N Engl J Med , vol.367 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 48
    • 79957492069 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    • Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 2121-2127
    • Keedy, V.L.1    Temin, S.2    Somerfield, M.R.3
  • 51
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757- 1765, 2008
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 52
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra C, Jessup J, Somerfield M, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.1    Jessup, J.2    Somerfield, M.3
  • 53
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 54
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
    • Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3
  • 55
    • 68049124818 scopus 로고    scopus 로고
    • KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer
    • Jimeno A, Messersmith WA, Hirsch FR, et al: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J 15:110- 113, 2009
    • (2009) Cancer J , vol.15 , pp. 110-113
    • Jimeno, A.1    Messersmith, W.A.2    Hirsch, F.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.